Barbara Hero

List of Publications by Year
in descending order

66 papers	6,468 citations	136950 32 h-index	110387 64 g-index
67 all docs	67 docs citations	67 times ranked	6757 citing authors

#	Article	IF	Citations
1	Cardiovascular Health Status And Genetic Risk In Survivors of Childhood Neuroblastoma and Nephroblastoma Treated With Doxorubicin: Protocol of the Pharmacogenetic Part of the LESS-Anthra Cross-Sectional Cohort Study. JMIR Research Protocols, 2022, 11, e27898.	1.0	3
2	Diagnosis and Management of Opsoclonus-Myoclonus-Ataxia Syndrome in Children. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	6.0	26
3	Long-term follow-up of children with neuroblastoma receiving radiotherapy to metastatic lesions within the German Neuroblastoma Trials NB97 and NBÂ2004. Strahlentherapie Und Onkologie, 2021, 197, 683-689.	2.0	6
4	Alternative lengthening of telomeres in childhood neuroblastoma from genome to proteome. Nature Communications, 2021, 12, 1269.	12.8	46
5	Clinical and molecular characterization of patients with stage 4(M) neuroblastoma aged less than 18Âmonths without MYCN amplification. Pediatric Blood and Cancer, 2021, 68, e29038.	1.5	4
6	Neuroblastoma. Pediatric Blood and Cancer, 2021, 68, e28473.	1.5	59
7	Neuroblastoma Screening at 1 Year of Age: The Final Results of a Controlled Trial. JNCI Cancer Spectrum, 2021, 5, pkab041.	2.9	5
8	Recommendations for Age-Appropriate Testing, Timing, and Frequency of Audiologic Monitoring During Childhood Cancer Treatment. JAMA Oncology, 2021, 7, 1550.	7.1	14
9	Genetic Alterations and Resectability Predict Outcome in Patients with Neuroblastoma Assigned to High-Risk Solely by MYCN Amplification. Cancers, 2021, 13, 4360.	3.7	1
10	Pooled RT-qPCR testing for SARS-CoV-2 surveillance in schools - a cluster randomised trial. EClinicalMedicine, 2021, 39, 101082.	7.1	29
11	Hypercalcemia is a frequent side effect of 13â€•cis â€•retinoic acid treatment in patients with highâ€•risk neuroblastoma. Pediatric Blood and Cancer, 2021, , e29374.	1.5	1
12	Biochemical testing for neuroblastoma using plasma free 3â€Oâ€•methyldopa, 3â€•methoxytyramine, and normetanephrine. Pediatric Blood and Cancer, 2020, 67, e28081.	1.5	14
13	The prognostic strength of serum LDH and serum ferritin in children with neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project. Pediatric Blood and Cancer, 2020, 67, e28359.	1.5	28
14	PRIMAGE project: predictive in silico multiscale analytics to support childhood cancer personalised evaluation empowered by imaging biomarkers. European Radiology Experimental, 2020, 4, 22.	3.4	41
15	Proton Beam Therapy for Children With Neuroblastoma: Experiences From the Prospective KiProReg Registry. Frontiers in Oncology, 2020, 10, 617506.	2.8	8
16	A new risk score for patients after first recurrence of stage 4 neuroblastoma aged â‰¥18Âmonths at first diagnosis. Cancer Medicine, 2019, 8, 7236-7243.	2.8	12
17	Telomerase Is a Prognostic Marker of Poor Outcome and a Therapeutic Target in Neuroblastoma. JCO Precision Oncology, 2019, 3, 1-20.	3.0	29
18	Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients. Journal of the National Cancer Institute, 2018, 110, 1084-1093.	6.3	73

#	Article	IF	Citations
19	Clinical trial of Lâ€Carnitine and valproic acid in spinal muscular atrophy type I. Muscle and Nerve, 2018, 57, 193-199.	2.2	23
20	Genomic Profiles of Neuroblastoma Associated With Opsoclonus Myoclonus Syndrome. Journal of Pediatric Hematology/Oncology, 2018, 40, 93-98.	0.6	11
21	A mechanistic classification of clinical phenotypes in neuroblastoma. Science, 2018, 362, 1165-1170.	12.6	213
22	Long-term outcomes of the GPOH NB97 trial for children with high-risk neuroblastoma comparing high-dose chemotherapy with autologous stem cell transplantation and oral chemotherapy as consolidation. British Journal of Cancer, 2018, 119, 282-290.	6.4	30
23	LDHA in Neuroblastoma Is Associated with Poor Outcome and Its Depletion Decreases Neuroblastoma Growth Independent of Aerobic Glycolysis. Clinical Cancer Research, 2018, 24, 5772-5783.	7.0	48
24	Longâ€term followâ€up of meningeal spread of otherwise stage 4S neuroblastoma without treatment. Pediatric Blood and Cancer, 2017, 64, e26445.	1.5	0
25	Liver transplantation as a potentially lifesaving measure in neuroblastoma stage 4S. Pediatric Hematology and Oncology, 2017, 34, 17-23.	0.8	7
26	Childhood cancer predisposition syndromesâ€”A concise review and recommendations by the Cancer Predisposition Working Group of the Society for Pediatric Oncology and Hematology. American Journal of Medical Genetics, Part A, 2017, 173, 1017-1037.	1.2	200
27	2017 GPOH Guidelines for Diagnosis and Treatment of Patients with Neuroblastic Tumors. Klinische Padiatrie, 2017, 229, 147-167.	0.6	76
28	Neuroblastoma survivors are at increased risk for second malignancies: A report from the International Neuroblastoma Risk Group Project. European Journal of Cancer, 2017, 72, 177-185.	2.8	59
29	Molecular Classification Substitutes for the Prognostic Variables Stage, Age, and MYCN Status in Neuroblastoma Risk Assessment. Neoplasia, 2017, 19, 982-990.	5.3	26
30	Lack of immunocytological GD2 expression on neuroblastoma cells in bone marrow at diagnosis, during treatment, and at recurrence*. Pediatric Blood and Cancer, 2017, 64, 46-56.	1.5	44
31	Complete surgical resection improves outcome in INRG high-risk patients with localized neuroblastoma older than 18Âmonths. BMC Cancer, 2017, 17, 520.	2.6	63
32	Treatment and outcome of Ganglioneuroma and Ganglioneuroblastoma intermixed. BMC Cancer, 2016, 16, 542.	2.6	110
33	Neuroblastoma messenger RNA is frequently detected in bone marrow at diagnosis of localised neuroblastoma patients. European Journal of Cancer, 2016, 54, 149-158.	2.8	10
34	Transcription factor activating protein 2 beta (TFAP2B) mediates noradrenergic neuronal differentiation in neuroblastoma. Molecular Oncology, 2016, 10, 344-359.	4.6	36
35	Correction factors for self-selection when evaluating screening programmes. Journal of Medical Screening, 2016, 23, 44-49.	2.3	12
36	MYCN and HDAC5 transcriptionally repress CD9 to trigger invasion and metastasis in neuroblastoma. Oncotarget, 2016, 7, 66344-66359.	1.8	30

#	Article	IF	Citations
37	IT Infrastructure for Merging Data from Different Clinical Trials and Across Independent Research Networks. Studies in Health Technology and Informatics, 2016, 228, 287-91.	0.3	0
38	Minimal residual disease detection in autologous stem cell grafts from patients with high risk neuroblastoma. Pediatric Blood and Cancer, 2015, 62, 1368-1373.	1.5	22
39	Comparison of RNA-seq and microarray-based models for clinical endpoint prediction. Genome Biology, 2015, 16, 133.	8.8	325
40	Absence of telomerase reverse transcriptase promoter mutations in neuroblastoma. Biomedical Reports, 2015, 3, 443-446.	2.0	25
41	Mutational dynamics between primary and relapse neuroblastomas. Nature Genetics, 2015, 47, 872-877.	21.4	253
42	Telomerase activation by genomic rearrangements in high-risk neuroblastoma. Nature, 2015, 526, 700-704.	27.8	478
43	Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers. Clinical Cancer Research, 2015, 21, 1904-1915.	7.0	80
44	Metastatic Neuroblastoma Confined to Distant Lymph Nodes (stage 4N) Predicts Outcome in Patients With Stage 4 Disease: A Study From the International Neuroblastoma Risk Group Database. Journal of Clinical Oncology, 2014, 32, 1228-1235.	1.6	28
45	Clinical, Biologic, and Prognostic Differences on the Basis of Primary Tumor Site in Neuroblastoma: A Report From the International Neuroblastoma Risk Group Project. Journal of Clinical Oncology, 2014, 32, 3169-3176.	1.6	154
46	Role of Surgery in the Treatment of Patients With Stage 4 Neuroblastoma Age 18 Months or Older at Diagnosis. Journal of Clinical Oncology, 2013, 31, 752-758.	1.6	115
47	Update on Pediatric Opsoclonus Myoclonus Syndrome. Neuropediatrics, 2013, 44, 324-329.	0.6	51
48	Changes over three decades in outcome and the prognostic influence of age-at-diagnosis in young patients with neuroblastoma: A report from the International Neuroblastoma Risk Group Project. European Journal of Cancer, 2011, 47, 561-571.	2.8	94
49	The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report. Journal of Clinical Oncology, 2009, 27, 289-297.	1.6	1,540
50	Localized Infant Neuroblastomas Often Show Spontaneous Regression: Results of the Prospective Trials NB95-S and NB97. Journal of Clinical Oncology, 2008, 26, 1504-1510.	1.6	263
51	Topotecan, cyclophosphamide, and etoposide (TCE) in the treatment of high-risk neuroblastoma. Results of a phase-II trial. Journal of Cancer Research and Clinical Oncology, 2007, 133, 653-661.	2.5	60
52	Intensified External-Beam Radiation Therapy Improves the Outcome of Stage 4 Neuroblastoma in Children > 1 Year with Residual Local Disease. Strahlentherapie Und Onkologie, 2006, 182, 389-394.	2.0	76
53	Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. Lancet Oncology, The, 2005, 6, 649-658.	10.7	350
54	Opsoclonus myoclonus syndrome in neuroblastoma a report from a workshop on the dancing eyes syndrome at the advances in neuroblastoma meeting in Genoa, Italy, 2004. Cancer Letters, 2005, 228, 275-282.	7.2	129

#	Article	IF	Citations
55	New definition of low-risk neuroblastoma using stage, age, and 1p and MYCN status. Journal of Pediatric Hematology/Oncology, 2004, 26, 791-6.	0.6	23
56	Neuroblastoma Screening at One Year of Age. New England Journal of Medicine, 2002, 346, 1047-1053.	27.0	381
57	Proliferation marker KI-S5 discriminates between favorable and adverse prognosis in advanced stages of neuroblastoma with and withoutMYCN amplification. Cancer, 2002, 94, 854-861.	4.1	21
58	Metabolic activity and clinical features of primary ganglioneuromas. Cancer, 2001, 91, 1905-1913.	4.1	281
59	Preclinical and clinical aspects on the use of amifostine as chemoprotectorin neuroblastoma patients. Medical and Pediatric Oncology, 2001, 36, 199-202.	1.0	5
60	Telomerase is a strong indicator for assessing the proneness to progression in neuroblastomas. Medical and Pediatric Oncology, 2000, 35, 651-655.	1.0	27
61	Metastatic neuroblastoma in infancy: What does the pattern of metastases contribute to prognosis?. Medical and Pediatric Oncology, 2000, 35, 683-687.	1.0	35
62	Testicular and paratesticular involvement by metastatic neuroblastoma. Cancer, 2000, 88, 2636-2641.	4.1	33
63	Telomerase Activity and Telomerase Subunits Gene Expression Patterns in Neuroblastoma: A Molecular and Immunohistochemical Study Establishing Prognostic Tools for Fresh-Frozen and Paraffin-Embedded Tissues. Journal of Clinical Oncology, 2000, 18, 2582-2592.	1.6	98
64	Neuroblastoma. Drugs, 2000, 59, 1261-1277.	10.9	105
65	Metastatic neuroblastoma in infancy: What does the pattern of metastases contribute to prognosis?. , 2000, 35, 683.		2
66	German neuroblastoma mass screening study at 12 months of age: statistical aspects and preliminary results. Medical and Pediatric Oncology, 1998, 31, 435-441.	1.0	16